308 related articles for article (PubMed ID: 28556775)
1. Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.
Thiebes S; Leicht G; Curic S; Steinmann S; Polomac N; Andreou C; Eichler I; Eichler L; Zöllner C; Gallinat J; Hanganu-Opatz I; Mulert C
J Psychiatry Neurosci; 2017 Jun; 42(4):273-283. PubMed ID: 28556775
[TBL] [Abstract][Full Text] [Related]
2. Reduced auditory evoked gamma-band response and schizophrenia-like clinical symptoms under subanesthetic ketamine.
Curic S; Leicht G; Thiebes S; Andreou C; Polomac N; Eichler IC; Eichler L; Zöllner C; Gallinat J; Steinmann S; Mulert C
Neuropsychopharmacology; 2019 Jun; 44(7):1239-1246. PubMed ID: 30758327
[TBL] [Abstract][Full Text] [Related]
3. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
[TBL] [Abstract][Full Text] [Related]
4. Glutamatergic modulation of auditory information processing in the human brain.
Gunduz-Bruce H; Reinhart RM; Roach BJ; Gueorguieva R; Oliver S; D'Souza DC; Ford JM; Krystal JH; Mathalon DH
Biol Psychiatry; 2012 Jun; 71(11):969-77. PubMed ID: 22036036
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.
Roser P; Haussleiter IS; Chong HJ; Maier C; Kawohl W; Norra C; Juckel G
Psychopharmacology (Berl); 2011 Dec; 218(4):611-20. PubMed ID: 21590281
[TBL] [Abstract][Full Text] [Related]
6. The effects of ketamine on the mismatch negativity (MMN) in humans - A meta-analysis.
Rosburg T; Kreitschmann-Andermahr I
Clin Neurophysiol; 2016 Feb; 127(2):1387-1394. PubMed ID: 26699665
[TBL] [Abstract][Full Text] [Related]
7. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.
Umbricht D; Schmid L; Koller R; Vollenweider FX; Hell D; Javitt DC
Arch Gen Psychiatry; 2000 Dec; 57(12):1139-47. PubMed ID: 11115327
[TBL] [Abstract][Full Text] [Related]
8. The effects of glycine on auditory mismatch negativity in schizophrenia.
Greenwood LM; Leung S; Michie PT; Green A; Nathan PJ; Fitzgerald P; Johnston P; Solowij N; Kulkarni J; Croft RJ
Schizophr Res; 2018 Jan; 191():61-69. PubMed ID: 28602646
[TBL] [Abstract][Full Text] [Related]
9. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.
Umbricht D; Koller R; Vollenweider FX; Schmid L
Biol Psychiatry; 2002 Mar; 51(5):400-6. PubMed ID: 11904134
[TBL] [Abstract][Full Text] [Related]
10. Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.
Schmidt A; Bachmann R; Kometer M; Csomor PA; Stephan KE; Seifritz E; Vollenweider FX
Neuropsychopharmacology; 2012 Mar; 37(4):865-75. PubMed ID: 22030715
[TBL] [Abstract][Full Text] [Related]
11. Ketamine Affects Prediction Errors about Statistical Regularities: A Computational Single-Trial Analysis of the Mismatch Negativity.
Weber LA; Diaconescu AO; Mathys C; Schmidt A; Kometer M; Vollenweider F; Stephan KE
J Neurosci; 2020 Jul; 40(29):5658-5668. PubMed ID: 32561673
[TBL] [Abstract][Full Text] [Related]
12. NMDA Receptor Antagonist Effects on Speech-Related Mismatch Negativity and Its Underlying Oscillatory and Source Activity in Healthy Humans.
de la Salle S; Shah D; Choueiry J; Bowers H; McIntosh J; Ilivitsky V; Knott V
Front Pharmacol; 2019; 10():455. PubMed ID: 31139075
[TBL] [Abstract][Full Text] [Related]
13. Effect of ketamine on the neuromagnetic mismatch field in healthy humans.
Kreitschmann-Andermahr I; Rosburg T; Demme U; Gaser E; Nowak H; Sauer H
Brain Res Cogn Brain Res; 2001 Aug; 12(1):109-16. PubMed ID: 11489614
[TBL] [Abstract][Full Text] [Related]
14. Glycine attenuates impairments of stimulus-evoked gamma oscillations in the ketamine model of schizophrenia.
Haaf M; Curic S; Steinmann S; Rauh J; Leicht G; Mulert C
Neuroimage; 2022 May; 251():119004. PubMed ID: 35176492
[TBL] [Abstract][Full Text] [Related]
15. Alterations in interhemispheric gamma-band connectivity are related to the emergence of auditory verbal hallucinations in healthy subjects during NMDA-receptor blockade.
Thiebes S; Steinmann S; Curic S; Polomac N; Andreou C; Eichler IC; Eichler L; Zöllner C; Gallinat J; Leicht G; Mulert C
Neuropsychopharmacology; 2018 Jun; 43(7):1608-1615. PubMed ID: 29453445
[TBL] [Abstract][Full Text] [Related]
16. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.
Heekeren K; Daumann J; Neukirch A; Stock C; Kawohl W; Norra C; Waberski TD; Gouzoulis-Mayfrank E
Psychopharmacology (Berl); 2008 Jul; 199(1):77-88. PubMed ID: 18488201
[TBL] [Abstract][Full Text] [Related]
17. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice.
Ehrlichman RS; Maxwell CR; Majumdar S; Siegel SJ
J Cogn Neurosci; 2008 Aug; 20(8):1403-14. PubMed ID: 18303985
[TBL] [Abstract][Full Text] [Related]
18. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans.
Driesen NR; McCarthy G; Bhagwagar Z; Bloch M; Calhoun V; D'Souza DC; Gueorguieva R; He G; Ramachandran R; Suckow RF; Anticevic A; Morgan PT; Krystal JH
Mol Psychiatry; 2013 Nov; 18(11):1199-204. PubMed ID: 23337947
[TBL] [Abstract][Full Text] [Related]
19. Chronic effects of cannabis use on the auditory mismatch negativity.
Greenwood LM; Broyd SJ; Croft R; Todd J; Michie PT; Johnstone S; Murray R; Solowij N
Biol Psychiatry; 2014 Mar; 75(6):449-58. PubMed ID: 23830666
[TBL] [Abstract][Full Text] [Related]
20. Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model.
Haaf M; Leicht G; Curic S; Mulert C
Curr Pharm Biotechnol; 2018; 19(4):293-307. PubMed ID: 29929462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
